• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting.

作者信息

Quijada-Álamo Miguel, Freed Grace, Wagenblast Elvin

机构信息

Department of Oncological Sciences, Tisch Cancer Institute, Black Family Stem Cell Institute, Mindich Child Health and Development Institute and Department of Pediatrics, Division of Pediatric Hematology-Oncology, Icahn School of Medicine at Mount Sinai.

出版信息

Haematologica. 2025 Jan 1;110(1):13-15. doi: 10.3324/haematol.2024.286140.

DOI:10.3324/haematol.2024.286140
PMID:39219462
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11694097/
Abstract
摘要

相似文献

1
LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting.脂酶A（LIPA）跳跃式急变期慢性髓性白血病：通过溶酶体靶向跨越耐药性
Haematologica. 2025 Jan 1;110(1):13-15. doi: 10.3324/haematol.2024.286140.
2
Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia.溶酶体酸性脂肪酶A调节慢性髓性白血病急变期白血病干细胞对维奈托克/酪氨酸激酶抑制剂联合治疗的反应。
Haematologica. 2025 Jan 1;110(1):103-116. doi: 10.3324/haematol.2023.284716.
3
An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia.髓系原始细胞期慢性髓系白血病概述
Cancers (Basel). 2024 Oct 26;16(21):3615. doi: 10.3390/cancers16213615.
4
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.伊马替尼对慢性期和急变期慢性髓性白血病患者肿瘤细胞的体外活性。
Anticancer Drugs. 2006 Jul;17(6):631-9. doi: 10.1097/01.cad.0000217423.59831.db.
5
[Research on the clinical characteristics and prognosis of children with chronic myeloid leukemia in the blast phase].[慢性髓性白血病急变期儿童的临床特征及预后研究]
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):931-936. doi: 10.3760/cma.j.cn121090-20240130-00045.
6
[Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].STI571治疗慢性髓性白血病患者的临床疗效及副作用
Ai Zheng. 2004 Apr;23(4):421-5.
7
[Immunophenotypes on blast cells of chronic myelogenous leukemia].[慢性粒细胞白血病原始细胞的免疫表型]
Nihon Rinsho. 2001 Dec;59(12):2342-7.
8
Ischemic stroke as a presenting feature of promyelocytic blast phase in chronic myeloid leukemia - an uncommon presentation: a case report and literature review in the post imatinib era.缺血性中风作为慢性髓性白血病早幼粒细胞急变期的首发特征——一种罕见的表现：伊马替尼时代后的病例报告及文献综述
Ann Hematol. 2024 Dec;103(12):6007-6013. doi: 10.1007/s00277-024-06044-9. Epub 2024 Oct 16.
9
mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways.突变在慢性髓性白血病进展过程中经常获得，并干扰髓样分化途径。
Haematologica. 2019 Sep;104(9):1789-1797. doi: 10.3324/haematol.2017.179937. Epub 2019 Feb 28.
10
Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.用普卡霉素和羟基脲治疗慢性粒细胞白血病髓系原始细胞期的初步观察
N Engl J Med. 1986 Dec 4;315(23):1433-8. doi: 10.1056/NEJM198612043152301.

本文引用的文献

1
Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia.溶酶体酸性脂肪酶A调节慢性髓性白血病急变期白血病干细胞对维奈托克/酪氨酸激酶抑制剂联合治疗的反应。
Haematologica. 2025 Jan 1;110(1):103-116. doi: 10.3324/haematol.2023.284716.
2
BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia.BH3模拟物与尼罗替尼或波纳替尼联合使用，在慢性髓性白血病急变期是一种有前景的治疗策略。
Cell Death Discov. 2022 Nov 15;8(1):457. doi: 10.1038/s41420-022-01211-1.
3
BCL2 and MCL1 inhibitors for hematologic malignancies.
BCL2 和 MCL1 抑制剂治疗血液系统恶性肿瘤。
Blood. 2021 Sep 30;138(13):1120-1136. doi: 10.1182/blood.2020006785.
4
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.慢性髓性白血病的突变景观：不仅仅是单一癌基因白血病。
Leuk Lymphoma. 2021 Sep;62(9):2064-2078. doi: 10.1080/10428194.2021.1894652. Epub 2021 May 4.
5
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.在高危B淋巴细胞白血病中同时靶向BCL-2和MCL-1
Blood Adv. 2020 Jun 23;4(12):2762-2767. doi: 10.1182/bloodadvances.2019001416.
6
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
7
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.
8
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.联合靶向作用于BCL-2和BCR-ABL酪氨酸激酶可根除慢性髓性白血病干细胞。
Sci Transl Med. 2016 Sep 7;8(355):355ra117. doi: 10.1126/scitranslmed.aag1180.
9
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.一种泛 BCL2 抑制剂使骨髓中常驻的人类白血病干细胞对酪氨酸激酶抑制敏感。
Cell Stem Cell. 2013 Mar 7;12(3):316-28. doi: 10.1016/j.stem.2012.12.011. Epub 2013 Jan 17.
10
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.在原发性慢性粒细胞白血病中，达沙替尼（BMS - 354825）比伊马替尼靶向更早的祖细胞群体，但不能消除静止部分。
Blood. 2006 Jun 1;107(11):4532-9. doi: 10.1182/blood-2005-07-2947. Epub 2006 Feb 9.